Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz
Gewählte Publikation:
SHR Neuro Krebs Kardio Lipid Stoffw Microb
Trummer, C; Schwetz, V; Pandis, M; Grübler, MR; Verheyen, N; Gaksch, M; Zittermann, A; März, W; Aberer, F; Steinkellner, J; Friedl, C; Brandenburg, V; Voelkl, J; Alesutan, I; Obermayer-Pietsch, B; Pieber, TR; Tomaschitz, A; Pilz, S.
Effects of vitamin D supplementation on FGF23: a randomized-controlled trial.
Eur J Nutr. 2019; 58(2):697-703
Doi: 10.1007/s00394-018-1672-7
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
- Führende Autor*innen der Med Uni Graz
- Trummer Christian
- Co-Autor*innen der Med Uni Graz
- Aberer Felix
- Grübler Martin
- Keppel Martin Helmut
- Lackner Claudia
- März Winfried
- Obermayer-Pietsch Barbara
- Pandis Marlene
- Pieber Thomas
- Pilz Stefan
- Steinkellner Julia
- Theiler-Schwetz Verena
- Tomaschitz Andreas
- Verheyen Nicolas Dominik
- Altmetrics:
- Dimensions Citations:
- Plum Analytics:
- Scite (citation analytics):
- Abstract:
- PURPOSE: Fibroblast growth factor-23 (FGF23) is critical for phosphate homeostasis. Considering the high prevalence of vitamin D deficiency and the association of FGF23 with adverse outcomes, we investigated effects of vitamin D3 supplementation on FGF23 concentrations. METHODS: This is a post-hoc analysis of the Styrian Vitamin D Hypertension trial, a single-center, double-blind, randomized, placebo-controlled trial, conducted from 2011 to 2014 at the Medical University of Graz, Austria. Two hundred subjects with 25(OH)D concentrations < 30 ng/mL and arterial hypertension were randomized to receive either 2800 IU of vitamin D3 daily or placebo over 8 weeks. Primary outcome was the between-group difference in FGF23 levels at study end while adjusting for baseline values. RESULTS: Overall, 181 participants (mean ± standard deviation age, 60.1 ± 11.3; 48% women) with available c-term FGF23 concentrations were considered for the present analysis. Mean treatment duration was 54 ± 10 days in the vitamin D3 group and 54 ± 9 days in the placebo group. At baseline, FGF23 was significantly correlated with serum phosphate (r = 0.135; p = 0.002). Vitamin D3 supplementation had no significant effect on FGF23 in the entire cohort (mean treatment effect 0.374 pmol/L; 95% confidence interval - 0.024 to 0.772 pmol/L; p = 0.065), but increased FGF23 concentrations in subgroups with baseline 25(OH)D concentrations below 20 ng/mL (n = 70; mean treatment effect 0.973 pmol/L; 95% confidence interval - 0.032 to 1.979 pmol/L; p = 0.019) and 16 ng/mL (n = 40; mean treatment effect 0.593 pmol/L; 95% confidence interval 0.076 to 1.109; p = 0.022). CONCLUSIONS: Vitamin D3 supplementation had no significant effect on FGF23 in the entire study cohort. We did, however, observe an increase of FGF23 concentrations in subgroups with low baseline 25(OH)D.
- Find related publications in this database (using NLM MeSH Indexing)
- Austria - administration & dosage
- Cholecalciferol - administration & dosage, blood
- Cohort Studies - administration & dosage
- Dietary Supplements - administration & dosage
- Double-Blind Method - administration & dosage
- Female - administration & dosage
- Fibroblast Growth Factor-23 - administration & dosage
- Fibroblast Growth Factors - blood, drug effects, genetics
- Humans - administration & dosage
- Male - administration & dosage
- Middle Aged - administration & dosage
- Find related publications in this database (Keywords)
- Vitamin D supplementation
- FGF23
- RCT
- Phosphate
- Calcitriol